Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasonex in OSAHS Associated with PAR
NCT00491374Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of mometasone furoate nasal spray in perennial allergic rhinitis (PAR), obstructive sleep apnea syndrome (OSAS), sponsored by Merck & Co.. Started Sep 2006; status: terminated.
02
Drugs
mometasone furoate nasal spray
03
Conditions
perennial allergic rhinitis (PAR)obstructive sleep apnea syndrome (OSAS)
Beyond the preview
Go deeper on NCT00491374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491374.